Skip to main content

Paradigm Genetics Reports Q2 Revenues Growth

NEW YORK, Aug 2 (GenomeWeb News) - Paradigm Genetics posted on Monday a second-quarter net loss essentially flat with the year-ago quarter, despite a 12 percent rise in revenues during the period.

 

Paradigm's revenues in the quarter were $6.3 million, up from $5.6 million in the second quarter 2003.

 

Meanwhile, the company's research and development spending climbed to $6.8 million in the second quarter, compared with $6.5 million in the year-ago period, helping to drive overall expenses about $800,000 higher to $9.8 million.

 

Paradigm reported a second-quarter net loss of $3.6 million. As of June 30, the company had cash, cash equivalents, and short-term investments totaling about $10.7 million.

 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.